Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from olfactory epithelium and typically present with symptoms attributable to locally invasive disease. Kadish radiographic staging and Hyams' histopathologic grading are prognostic. Overall survival rates, averaging 60-70% at 5 years, remain limited by high rates of delayed loco-regional and distant progression. At initial pr...

BACKGROUND Pain palliation resulting from antitumor therapy provides direct evidence of treatment benefit when combined with evidence of antitumor activity. The US Food and Drug Administration (FDA) previously issued guidance regarding the use of patient-reported outcome (PRO) measures to support labeling claims. The purpose of this article is to identify common challenges and key design strate...

Radiofrequency ablation (RFA) for thoracic tumours has emerged as a minimally invasive therapy option for primary and secondary lung tumours and has gained increasing acceptance for pain palliation. The procedure is well tolerated and the complication rates are low. RFA provides the opportunity for localized tissue destruction of limited tumour volumes with medium and long term follow-up data s...

PURPOSE: Prior studies show that many patients receiving palliative cancer therapies misperceive likelihood of cure. Patients’ understanding treatment benefits and risks beyond cure is unknown. We explore patient perceptions in the novel therapeutic era. METHODS: surveyed with advanced solid cancers their oncologists regarding therapies. assessed perceived tumor response, survival benefit, symp...

In the end stage cancer patients where in the cure is an obligate failure necessitates the palliation approach which focuses on creating an easy and comfort life to the patient rather than treating them as an experimental model for the research [1]. Palliation approach would help in the quality improvement of the end stage life whose recovery cannot be expected. Various palliation therapies hav...

Myelofibrosis shows a progressive clinical course and usually a poor, lethal prognosis. The molecular pathogenesis of this disease largely remains to be fully understood but the identification of the JAK2V617F mutation in more than half of patients was a major improvement in our understanding of the disease biology and may represent the first biologic marker useful for risk stratification, inde...

Palliation of malignant dysphagia SIR,-Dr Barr et al are to be congratulated on their work examining the role of laser and laser + intubation in the palliation of malignant dysphagia.' We would agree with their conclusion that laser therapy should be restricted to specialist centres, and others have highlighted that, apart from operator expertise, high capital cost is another reason for restric...